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Abstract
Falls are among the most incapacitating features of Parkinson’s disease. Prevention of falls requires a
systematic assessment of all contributing factors (with emphasis on freezing of gait and frontal
executive dysfunction), and a multidisciplinary treatment approach tailored to the specific
pathophysiology of falls for each individual patient.
Introduction and context
Falls are both common and debilitating in patients with
Parkinson’s disease (PD). They have devastating con-
sequences for affected individuals, often leading to
injuries, secondary immobility, and reduced quality of
life. Survival is reduced once falls have occurred [1],
although a recent report failed to identify a relationship
between falls and mortality risk in PD [2]. Falls are also
important for the public health system, as the costs
associated with falls and fall-related injuries are enor-
mous. A prospective 20-year follow-up of 136 patients
with newly diagnosed PD confirmed the high prevalence
of falls (87%) and resulting fractures (35%) [3].
For the management of falls in PD, it is important to
appreciate the complex and multifactorial pathophysiol-
ogy. Both balance deficits and gait disorders inherent
to PD can obviously lead to falls. Environmental
factors such as slippery floors, loose rugs, poor lighting,
or inadequate footwear may also contribute. There is an
increasing awareness that freezing of gait – a sudden and
episodically occurring inability to generate effective
forward stepping movements – is one of the leading
causes of falls, presumably because patients are caught
by surprise due to the often unexpected nature of
freezing events [4,5]. Recent work has underscored the
additional importance of cognitive impairment as a key
factor contributing to both falls and freezing [6,7]; falls
are an issue in demented patients in particular [8].
Possible explanations for this link include more promi-
nent dopaminergic denervation of the caudate nucleus
[9] or more generalized cholinergic dysfunction [10].
Preventing falls is generally perceived as being difficult,
but is not impossible. Given the complex multifactorial
nature of falls and the experience in elderly non-
parkinsonian populations [11], a multidisciplinary
approach appears preferable, but for patients with PD
this strategy is not yet backed by scientific evidence.
Crucial elements in the therapeutic approach include
optimizing pharmacotherapy – increasing PDmedication
for dopa-sensitive signs, and stopping sedative drugs –
and tailored physiotherapy, based on evidence-based
practice guidelines.
Here, we highlight a few important new developments
in this field.
Recent advances
Assessment of the patient with falls
Each patient deserves a careful and systematic approach
to identify all contributing factors. The quest should
not stop when one causative factor has been found
because falls are typically multifactorial in origin.
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A recent prospective study in 101 patients with early-
stage PD assessed how various measures could predict
falls [12]. The best prediction was reached by combining
disease-specific measures (such as PD severity and
freezing of gait severity) with balance measures (such
as the occurrence of symptomatic orthostatic hypoten-
sion, the Tinetti total score, and the extent of postural
anterior-posterior sway). However, even this combina-
tion attained a sensitivity and specificity for predicting
falls of only around 80%. Including cognitive measures
that are more specific may further improve these
predictive scores [13], but this remains to be examined.
Particular emphasis should be placed on testing for
freezing of gait – using a series of provoking tests,
including rapid 360 degree turns on the spot [14] – and
for frontal executive dysfunction [7]. Specific attention
should be paid to fear of renewed falling as this is
common in PD [15]. Fear of falling is not only a risk
factor for renewed falls [16], it may also lead to
secondary immobilization with all its related adverse
consequences [17].
Optimizing medication
Most balance deficits are resistant to dopaminergic
medication. However, gait problems – including freezing
of gait – can improve with dopaminergic medication,
although doses that are higher or more frequent than
those typically needed to increase hand functioning may
be required [18]. Recent work points to a possible role
for cholinesterase inhibitors in the treatment of gait and
balance deficits, both in PD [19,20] and in Alzheimer’s
disease [21], given that many axial motor deficits may
result from misbalance between central cholinergic and
dopaminergic systems [10]. Sedative drugs should be
stopped whenever possible.
Stereotactic deep brain surgery
It has become clear that stereotactic deep brain surgery
should be reserved for patients whose gait and balance
deficits are still levodopa-responsive pre-operatively.
Several studies are comparing bilateral stimulation of
two different targets, namely the subthalamic nucleus
(STN) and the internal globus pallidus [22,23]. The
initial results indicate that both approaches are effective
in providing short-term relief of motor symptoms, but
one study suggested internal globus pallidus stimulation
may offer better long-term outcomes for gait and balance
deficits [22]. This difference was not evident in the largest
study, although falls after a 2-year follow-up tended to be
more common after STN stimulation [23], but this
requires more study. In particular, STN stimulation has
been associated with a worsening of gait and balance
deficits, not only in the immediate postoperative phase,
but also several years after follow-up [22,24]. Adjusting
the stimulation parameters (e.g., markedly lowering the
stimulation frequency) may be helpful in such patients
[25]. The pedunculopontine nucleus has been studied as
a promising new target, specifically for gait and balance
deficits, but so far the results have not been very
impressive [26,27].
Physiotherapy
The evidence-based guidelines on physiotherapy for
PD were recently updated [28], providing a menu of
treatment modalities to improve mobility and reduce
falls. Examples of evidence-based physiotherapy strate-
gies include cueing techniques, cognitive movement
strategies, and the use of exercise. Rhythmic auditory or
visual cues can improve gait in PD, including freezing of
gait [29,30]. New inventive cueing approaches include
walking glasses with different patterns of visual and
auditory stimulation [31] and mental singing while
walking [32]. Another promising approach, especially for
PD patients with freezing of gait, is the use of cycling, the
skill for which can be remarkably preserved in some
patients [33]. Evidence based mainly on the effects of
cueing on laboratory measures of gait and balance
remains; the challenge is to ascertain an enduring clinical
improvement in daily life, including a reduction of falls.
Fears that cues might worsen the tendency to fall – for
example, by increasing overall mobility – have not been
substantiated [29]. The same holds true for the effect of
exercise. A systematic review concluded that exercise in
patients with PD results in improvement in postural
stability and balance task performance [34]. However,
power and quality of exercise studies have hitherto been
insufficient to make definitive recommendations. Future
randomized controlled trials will look into the (cost)
effectiveness of exercise to reduce falls [35,36].
There is a growing body of literature on the use of
treadmill training for gait rehabilitation in patients with
neurologic disorders in general and for patients with PD
in particular. A recent Cochrane review concluded that
treadmill training may help to improve gait akinesia in
PD, but the effect on falls remains unclear [37]. It also
remains uncertain how long any improvements induced
by treadmill training may last.
Another interesting new development is the use of
robotics, which can assist PD patients in making medio-
lateral anticipatory weight shifts in preparation for taking
a step [38]. The initial results are promising, and such
new techniques now need to be implemented in
situations that are more realistic to evaluate the clinical
merits of these techniques in relation to everyday gait
performance and falls.
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Delivering such specific physiotherapy interventions to
patients with PD likely requires trained expert phy-
siotherapists. A large cluster-randomized trial showed
that a community-based professional network with
trained expert physiotherapists improved the quality of
physiotherapy care and reduced health care costs, but
without health benefits for patients [39].
Implications for clinical practice
Asking about falls and their impact on daily functioning
should be a standard part of the evaluation of patients
with PD. While awaiting further evidence, neurologists
should consider installing a multidisciplinary team
approach to tackle the vexing problem of falls in
patients with PD. Management involves a systematic
search for risk factors for falling, and a subsequent
multifactorial approach aimed at eliminating or alle-
viating all patient-related and environmental risk factors
for falling. Apart from optimizing dopaminergic med-
ication, cholinergic therapies are now beginning to enter
the field of play as well. Fear of falling must be
addressed, and immobilization must be avoided as long
as independent movements can still be made reason-
ably safely. The multidisciplinary team should ideally
consist of trained and experienced professionals who
treat large numbers of patients. Using this integrated
approach, the goal should be to at least reduce falls or
perhaps prevent them altogether, restore mobility and
independence, and thereby help to maintain the quality
of life for patients with PD.
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